Instead of donor T cell depletion, we used CTLA4 and TJU103 (a small organic compound believed to block CD4 binding to MHC II molecule of APC) to block donor T lymphocyte activation in vitro before infusion, and mycophenolate mofetil to control the activity of lymphocytes of the recipient. We successfully treated a patient with an HLA-mismatched graft without donor T cell depletion. Mixed chimerism was observed 30 days and 60 days after transplantation. STR-PCR showed that 28% and 62% of blood mononuclear cells (MNC) were donor derived at day +30 and day +60, respectively. Mixed chimerism converted into full donor chimerism, when 99.7% of the MNC in the recipient were donor derived after three courses of DLI. A powerful GVL effect related to mixed chimerism was observed. No acute GVHD occurred, only grade II chronic GVHD occurred 6 months after transplant. Based on this case, we suggest that: (1) stable mixed chimerism can be intentionally established across HLA barriers without donor T cell depletion; (2) mixed chimerism can be converted into full donor chimerism by DLI; (3) mixed chimerism induced with this approach can be associated with a very powerful GVL effect, and these may be enhanced by DLI, without severe GVHD. Bone Marrow Transplantation (2000) 26, 691-693. Keywords: HLA-mismatched transplantation: CML; GVL; non-donor T cell depletion Allo-BMT/PBSCT provides a potentially curative therapy for patients with leukemia. The serious complications and high transplant-related mortality (TRM) means that the therapy is not administered widely in China. The therapy is also restricted by the availability of suitable donors. Nonmyeloablative regimens decrease the complications and transplantation-related mortality.
plantation between family members may alleviate the issue of donor availability. To date, HLA-mismatched transplants have been accomplished by T cell depletion. T cell depletion is considered to diminish the GVL effect and increase the risk of leukemia relapse. Recently, we treated a patient with CML by HLA A, B two loci mismatched PBSCT without T cell depletion. Mixed chimerism was achieved, and converted into full donor chimerism after donor lymphocyte infusion. A powerful GVL effect was observed but no severe acute GVHD occurred.
Case report
A 23-year-old female was diagnosed with CML in May 1999 because of anemia and splenomegaly. Physical examination revealed the spleen was extended to the pelvic brim and across the midline of abdomen. White cell count was 230 × 10 9 /l and was Ph chromosome negative. BCR/ABL hybrid gene examined by PCR was also negative. She was treated with hydroxyurea and interferon-␣ and spleen local radiation (2300 cGy). Her anemia improved but splenomegaly decreased slowly. Two months later, she still did not enter remission. Her spleen was still as large as 6 cm below the right rib margin. HLA-mismatched allogeneic PBSCT was performed. The donor was her brother. One HLA-A and one HLA-B loci were mismatched (see Table 1 ). From days −6 to −1 fludarabine (Schering, Milan, Italy) at a dose of 30 mg/m 2 was given, and busulfan at a dose of 4 mg/kg per day was given orally at days −4 and −3. Cyclophosphamide at a dose of 10 mg/kg per day was administered intravenously at days −3 and −2. For prophylaxis against GVHD, cyclosporin A at a dose of 3 mg/kg from day 1, which was maintained at 150-200 ng/ml in serum, and mycophenolate mofetil (Roche, Basel, Switzerland) at a dose of 2.0 g per day from day −5 to +30 orally was given respectively. G-CSF (Chugai, Tokyo, Japan) mobilized MNC were cultured with CTLA4 and TJU103 2 in the presence of 25 Gy irradiated patient MNC (total 1 × 10 6 ) for 1 h and washed with 0.9% saline twice before infusion. A total of 5 × 10 8 /kg G-CSF-mobilized MNC (CD34 + cells 6.2 × 10 6 /kg) was infused on days 0 and +1. She was given rhG-CSF (Chugai) at a dose of 5 g/kg from day 10 until Table 1 The change of HLA genotype and chromosome of the patient /l. The times to reach 0.5 × 10 9 /l ANC and 20 × 10 9 /l platelets were 25 days and 28 days respectively. Her lymphocytes were controlled to less than 15% of the white cell count by mycophenolate mofetil orally at intervals. Donor lymphocytes were obtained from the untreated donor by leukapheresis (collected by CS3000 plus) and were infused into the patient at a dose of 0.5 × 10 8 /kg at days 30, 60 and 90, respectively. Her splenomegaly began decreasing at day +75 and disappeared at day +90. She obtained complete remission. The genotype of the MNC was analyzed by short tandem repeat PCR (STR-PCR) before DLI. Twenty-eight percent, 62% and 99.7% of the patient's MNC were donor derived at days 30, 60 and 120, respectively. She became a full donor chimera at day +120 after three courses of DLI. Only slight oral mucositis was observed, no skin damage occurred and there were no serious complications. The GVL effect is obvious and considered to be related to mixed chimerism. Following-up for 270 days, she is very well. Only grade II chronic GVHD was observed +180 days after transplant when cyclosporin A was reduced. No steroid therapy was needed.
Discussion
Myeloablative therapy is administered to control HVG reaction in conventional transplants and is associated with high transplant-related mortality (TRM). Slavin et al 1 introduced the use of relatively nonmyeloablative conditioning, which decreases the TRM, for induction of GVL effects to displace residual malignant or genetically abnormal host cells. Aversa et al 3 have successfully achieved HLA haploidentical PBSCT with T cell depletion under myeloablative conditions. GVHD was acceptable in their regimen. However, T cell-depleted transplants have often been associated with an increased risk of leukemia relapse. Besides being responsible for GVHD, donor T cells have a positive role in faciliatating engraftment, controlling opportunistic infections and contributing to GVL. Is it possible to achieve engraftment of allogeneic hematopoietic cells following nonmyeloablative conditioning without removing donor T cells? Sykes et al 4 reported that HLA-mismatched bone marrow transplantation was successful by a nonmyeloablative regimen. T cells require two signals to be become activated, proliferate, clonally expand, and acquire effector function. CTLA4, which is considered to block the B7-mediated costimulation signal, and TJU103, a small compound, which is believed to block CD4 binding to MHC II molecules on APC and decrease GVHD in our murine model, 2 can inhibit T cell activation by different mechanisms. This implies that HLA-mismatched PBSCT could be achieved by nonmyeloablative conditioning without removal of donor T cells. Instead of donor T cell depletion, we successfully treated the patient with HLA-mismatched transplantation by using CTLA4 and TJU103. To reduce the alloreaction, mycophenolate mofetil was administered at intervals. Mixed chimerism was observed 30 and 60 days after transplantation. Mixed chimerism converted into full donor chimerism after three DLI treatments. The splenomegaly began decreasing at day +75 and disappeared at day +90. We believe it was the result of a powerful GVL effect and was related to mixed chimerism. No acute GVHD occurred. No opportunistic infections occurred. Based on this case, we suggest that: (1) stable mixed chimerism can be intentionally established across HLA barriers without donor T cell depletion; (2) mixed chimerism can be converted into full donor chimera by DLI; (3) mixed chimerism induced with this approach can be associated with very powerful GVL effects, and these may be enhanced by DLI, not associated with GVHD; (4) acute GVHD could be avoided by inactivating donor T cells and controlling the number of recipient lymphocytes instead of donor T cell depletion. 
